← Back to Clinical Trials
Recruiting NCT07656324

NCT07656324 Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07656324
Status Recruiting
Phase
Sponsor Fudan University
Condition Cancer
Study Type OBSERVATIONAL
Enrollment 1,000,000 participants
Start Date 2025-01-17
Primary Completion 2027-01-17

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
No Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000,000 participants in total. It began in 2025-01-17 with a primary completion date of 2027-01-17.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis.

Eligibility Criteria

Inclusion Criteria: 1. Male or female, aged 18 years or older. 2. Able to understand the purpose of this survey study, willing to participate, and able to sign an informed consent form. 3. Malignant tumor confirmed histologically or cytologically. Exclusion Criteria: 1. Pregnant or breastfeeding women. 2. Patients with acute or chronic infections, or those with other serious medical conditions that, in the investigator's judgment, make them unsuitable for this study. 3. Patients with two or more concurrent malignant tumors (excluding the following: cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma). 4. Patients with psychiatric illness or mental disorders, poor compliance, or who are unable to cooperate and report treatment responses. 5. Patients with severe organic disease or major organ failure, such as decompensated heart, lung, liver, or kidney failure. 6. Patients with other conditions that, in the investigator's opinion, make them unsuitable for participation in this study.

Contact & Investigator

Central Contact

Hongxia Wang, PhD

✉ whx365@126.com

📞 021-33988888

Frequently Asked Questions

Who can join the NCT07656324 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07656324 currently recruiting?

Yes, NCT07656324 is actively recruiting participants. Contact the research team at whx365@126.com for enrollment information.

Where is the NCT07656324 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT07656324 clinical trial?

NCT07656324 is sponsored by Fudan University. The trial plans to enroll 1,000,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology